Germline genetic testing to assess inherited risk for cancer is typically offered to a subset of patients meeting certain personal and family cancer history criteria. But through its Interrogating Cancer Etiology Using Proactive Genetic Testing (INTERCEPT) study, the Mayo Clinic sequenced nearly 3,000 cancer patients for around 80 cancer susceptibility genes and found that more than 1 in 8 patients harbored germline pathogenic variants associated with increased cancer risk. The researchers reported on Friday in JAMA Oncology that they wouldn't have identified half of these patients with pathogenic variants if they had tested patients according to current guidelines.